Observational studyActa oncologica (Stockholm, Sweden)2026
Disparities in initiating standard first-line cancer treatment and survival for patients with an immigrant background: a Danish register-based cohort study.
Observational study in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeIndividuals with an immigrant background may face barriers to healthcare. However, evidence on differences in cancer treatment and survival between patients with an immigrant background and patients of Danish origin is limited. PATIENTS AND
methodsWe included patients aged ≥50 years diagnosed with a first primary colon, lung, prostate, or kidney cancer between 2011 and 2022 from national clinical cancer databases. First-line treatment initiation (30/90 days) and survival (1/5 years) were assessed using risk ratios (RRs) comparing patients with an immigrant background to those of Danish origin. Immigrant backgrounds were categorized according to their origin in (1) other Western countries, (2) Central and Eastern Europe, and (3) the Middle East, North Africa, and Central Asia.
resultsOverall, there were no systematic differences in the initiation of first-line treatment or survival between patients with an immigrant background and patients of Danish origin. Exceptions included lower probability of initiating treatment (30-day RR: 0.76 [95% confidence interval (CI): 0.62; 0.93] and 90-day RR: 0.92 [95% CI: 0.87; 0.98]) and 1-year risk of death (RR: 0.85 [95% CI: 0.77; 0.93]) among lung cancer patients from Central and Eastern Europe, lower 30-day treatment initiation among patients from the Middle East, North Africa, and Central Asia (RR: 0.80 [95% CI: 0.64; 1.00]), and higher 5-year risk of death among prostate cancer patients from other Western countries (RR: 1.16 [95% CI: 1.01; 1.34]).
interpretationOverall, patients with an immigrant background had similar initiation of first-line cancer treatment and survival to those of Danish origin, with some statistically significant differences but no consistent pattern across cancer types or regions of origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.